Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Nov 2025 07:00 AM
RNS
Research Update
30 Oct 2025 03:30 PM
RNS
Result of AGM
03 Oct 2025 07:00 AM
RNS
Notice of AGM
16 Sep 2025 07:00 AM
RNS
Director Dealing
11 Sep 2025 07:00 AM
RNS
Final Results
04 Sep 2025 07:00 AM
RNS
Notice of Results
08 Aug 2025 12:31 PM
RNS
Director Dealing
04 Aug 2025 10:23 AM
RNS
Director/PDMR Shareholding
22 Jul 2025 07:00 AM
RNS
Strong Phase 2 data on iSCIB1+ in Melanoma
16 Jul 2025 07:00 AM
RNS
Share Option Exercise
25 Jun 2025 07:00 AM
RNS
Scancell initiates new arm in SCOPE Phase 2 study
21 May 2025 07:00 AM
RNS
Director Dealing
22 Apr 2025 07:10 AM
UKN
Investor Update via Investor Meet Company.
14 Apr 2025 07:00 AM
RNS
Partnership with NHS Cancer Vaccine Launch Pad
01 Apr 2025 07:00 AM
RNS
Scancell to present at 2025 AACR Annual Meeting
20 Feb 2025 07:00 AM
RNS
Issue of share options
17 Feb 2025 07:00 AM
RNS
Scancell presenting at AACR IO conference
30 Jan 2025 07:00 AM
RNS
Interim Results
23 Jan 2025 07:00 AM
RNS
Notice of Interim Results
09 Jan 2025 07:00 AM
RNS
Modi-1 Vaccine Achieves Early Clinical Validation
09 Dec 2024 11:41 AM
RNS
Result of Retail Offer and Total Voting Rights
05 Dec 2024 12:39 PM
RNS
Result of Placing and Subscription
04 Dec 2024 06:03 PM
RNS
Retail Offer for up to £1 million
04 Dec 2024 05:59 PM
RNS
Proposed fundraise in excess of £8.5 million
04 Dec 2024 07:00 AM
RNS
Second Commercial License Agreement with Genmab
18 Nov 2024 07:00 AM
RNS
Positive data from Phase 2 SCOPE trial with SCIB1
25 Oct 2024 03:26 PM
RNS
Result of Annual General Meeting
24 Oct 2024 07:00 AM
RNS
Holding(s) in Company
22 Oct 2024 07:00 AM
RNS
Scancell Appoints Dr Phil L’Huillier as CEO
01 Oct 2024 07:00 AM
RNS
Notice of AGM
24 Sep 2024 07:00 AM
RNS
Results Year Ended 30 April 2024
18 Sep 2024 07:00 AM
RNS
Notice of Final Results
17 Sep 2024 07:00 AM
RNS
Strategic Partnership with PharmaJet
02 Sep 2024 07:00 AM
RNS
Scancell to attend upcoming conferences
30 Jul 2024 07:17 AM
RNS
Scancell Appoints Dr Nermeen Varawalla as CMO
30 Jul 2024 07:00 AM
RNS
Scancell Appoints Dr Nermeen Varawalla as CMO
24 Jul 2024 07:00 AM
RNS
Update from iSCIB1+ Clinical Advisory Meeting
10 Jul 2024 07:00 AM
RNS
Appointment of Dr Florian Reinaud to the Board
02 Jul 2024 07:00 AM
RNS
Extension of Convertible Loan Notes
01 Jul 2024 07:00 AM
RNS
Block Listing Return and Total Voting Rights
21 Jun 2024 07:00 AM
RNS
Change of Nominated Advisor
12 Jun 2024 07:32 AM
RNS
Agreement with major biotech
31 May 2024 07:00 AM
RNS
Scancell to attend upcoming conferences
30 May 2024 07:00 AM
RNS
Update on ModiFY trial
24 May 2024 07:00 AM
RNS
Scancell to present at ASCO Annual Meeting
21 May 2024 07:00 AM
RNS
Issue of share options
16 May 2024 07:00 AM
RNS
Presenting at the Sachs 10th Annual Oncology Forum
09 May 2024 07:00 AM
RNS
Scancell presenting at 21st CIMT Annual Meeting
17 Apr 2024 07:00 AM
RNS
Presenting at the Annual Immuno-Oncology Summit
16 Apr 2024 07:00 AM
RNS
Block Listing Six Monthly Return

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings